TABLE 1.
Clinical characteristics of patients with stage IV non‐small‐cell lung cancer aged <75 and ≥75 years (n = 86 173)
| Factors | <75 years old (n = 62 037) | ≥75 years old (n = 24 136) | ||||
|---|---|---|---|---|---|---|
| Immune checkpoint inhibitor | p value | Immune checkpoint inhibitor | p value | |||
| Yes (n = 8968) | No (n = 53 069) | Yes (n = 2241) | No (n = 21 895) | |||
| Sex | ||||||
| Male | 4645 (14%) | 28 309 (86%) | 0.0067 | 1222 (10%) | 11 211 (90%) | 0.0027 |
| Female | 4323 (15%) | 24 760 (85%) | 1019 (9%) | 10 684 (91%) | ||
| Race | ||||||
| Whites | 7424 (15%) | 42 528 (85%) | <0.0001 | 1973 (9%) | 18 910 (91%) | 0.0272 |
| Others | 1544 (13%) | 10 541 (87%) | 268 (8%) | 2985 (92%) | ||
| Institution | ||||||
| Others | 5916 (15%) | 34 715 (85%) | 0.3131 | 1560 (9%) | 15 535 (91%) | 0.1877 |
| Academic | 3052 (14%) | 18 354 (86%) | 681 (10%) | 6360 (90%) | ||
| Charlson–Deyo score | ||||||
| ≥2 | 909 (12%) | 6791 (88%) | <0.0001 | 342 (8%) | 3753 (92%) | 0.0247 |
| ≤1 | 8059 (15%) | 46 278 (85%) | 1899 (9%) | 18 142 (91%) | ||
| Year of diagnosis | ||||||
| 2014 | 3754 (12%) | 27 238 (88%) | <0.0001 | 786 (7%) | 11 155 (93%) | <0.0001 |
| 2015 | 5214 (17%) | 25 831 (83%) | 1455 (12%) | 10 740 (88%) | ||
| Histology | ||||||
| Others | 2430 (10%) | 21 293 (90%) | <0.0001 | 694 (7%) | 12 826 (93%) | <0.0001 |
| Adenocarcinoma NOS | 6538 (17%) | 31 776 (83%) | 1547 (12%) | 9069 (88%) | ||
| Nodal status | ||||||
| N0 | 2211 (13%) | 15 375 (87%) | <0.0001 | 719 (8%) | 8308 (92%) | <0.0001 |
| ≥N1 | 6757 (15%) | 37 694 (85%) | 1522 (10%) | 13 587 (90%) | ||
| Brain metastasis | ||||||
| Yes | 709 (9%) | 7295 (91%) | <0.0001 | 89 (5%) | 1682 (95%) | <0.0001 |
| No | 8259 (15%) | 45 774 (85%) | 2152 (10%) | 20 213 (90%) | ||
| Bone metastasis | ||||||
| Yes | 1403 (14%) | 8520 (86%) | 0.3343 | 303 (8%) | 3337 (92%) | 0.0301 |
| No | 7565 (15%) | 44 549 (85%) | 1938 (9%) | 18 558 (91%) | ||
| Liver metastasis | ||||||
| Yes | 464 (11%) | 3692 (89%) | <0.0001 | 97 (6%) | 1448 (94%) | <0.0001 |
| No | 8504 (15%) | 49 377 (85%) | 2144 (9%) | 20 447 (91%) | ||
| Surgery for primary lesion | ||||||
| Yes | 225 (11%) | 1773 (89%) | <0.0001 | 38 (8%) | 418 (92%) | 0.5155 |
| No | 8743 (15%) | 51 296 (85%) | 2203 (9%) | 21 477 (91%) | ||
| Radiation | ||||||
| Yes | 4479 (14%) | 28 430 (86%) | <0.0001 | 865 (9%) | 8314 (91%) | 0.5680 |
| No | 4489 (15%) | 24 639 (85%) | 1376 (9%) | 13 581 (91%) | ||
| Chemotherapy | ||||||
| Yes | 7398 (17%) | 34 928 (83%) | <0.0001 | 1444 (13%) | 9752 (87%) | <0.0001 |
| No | 1570 (8%) | 18 141 (92%) | 797 (6%) | 12 143 (94%) | ||
Abbreviation: NOS, not otherwise specified.